Allo-HSCT
Sponsors
Genetix Biotherapeutics Inc., National Research Center for Hematology, Russia, Shanghai Jiao Tong University School of Medicine, Peking University People's Hospital, Zhejiang University
Conditions
AMLAcute Myeloid LeukemiaAdrenoleukodystrophy (ALD)Bone Marrow Failure SyndromeCerebral Adrenoleukodystrophy (CALD)Schimke Immuno-osseous DysplasiaT Lymphoblastic LymphomaX-Linked Adrenoleukodystrophy (X-ALD)
Early Phase 1
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD
RecruitingNCT06769191
Start: 2025-01-30End: 2028-01-30Target: 20Updated: 2025-01-20
CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases
RecruitingNCT06787560
Start: 2025-01-31End: 2028-01-31Target: 20Updated: 2025-01-22
Phase 2
Unknown Phase
Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
TerminatedNCT02204904
Start: 2015-04-30End: 2019-12-06Updated: 2020-05-21
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission
RecruitingNCT05339204
Start: 2021-02-01End: 2026-02-01Target: 75Updated: 2022-04-21
Allo-HSCT vs ASCT in Adult T-LBL
Not yet recruitingNCT06741813
Start: 2025-01-01End: 2029-12-31Target: 230Updated: 2024-12-19